Role of GLP-1RA in practice
5 Things a cardiologist needs to know about GLP-1RA
*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD - Barcelona, Spain - Online CME
Video navigation menu
- Moving from a glucocentric approach towards a more personalized and CV risk-focused approach 00:35
- ADA/EASD recommendations for high risk patients or with established ASCVD, CKD or HF 01:10
- ESC recommendations for patients with ASCVD, or high / very high CV risk 03:47
- ACC expert consensus decision pathway for CV risk reduction in patients with T2D 04:50
- ADA/EASD position statement for people without established ASCVD, HF or CKD 05:18
- Recommendations if there is a need to minimize hypoglycaemia, or to minimize weight gain/promote weight loss 06:00
- When to initiate a GLP-1 RA with proven CVD benefit in people with or without high risk or clinical ASCVD, CKD or HF? 08:46
This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.
Prof. Eduard Montanya, MD - Bellvitge University Hospital, University of Barcelona, Spain
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.
This is available as accredited online CME on coursepath for members. Click the button below to enroll:Enroll